XSpray Overview

  • Founded
  • 2003
  • Status
  • Public
  • Employees
  • 20
  • Stock Symbol
Stock Symbol
  • Share Price
  • $16.15
  • (As of Monday Closing)

XSpray General Information


XSpray Pharma AB is a product development company with several product candidates in clinical development. It develops, sells and licenses generic versions of marketed cancer drugs, protein kinase inhibitors. The company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatment.

Contact Information

Formerly Known As
CENS Delivery
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Primary Office
  • Gunnar Asplunds Allé 32
  • 171 63 Solna
  • Sweden
+46 08-730 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

XSpray Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.15 $16.37 $4.29 - $30.82 $275M 17M 91.7K -$0.34

XSpray Financials Summary

In Thousands,
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 180,810 136,266 100,325 76,268
Revenue 0 0 32 39
EBITDA (4,988) (4,415) (2,205) (1,489)
Net Income (5,400) (4,839) (2,655) (1,617)
Total Assets 39,180 42,854 35,078 19,717
Total Debt 577 570 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

XSpray Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore XSpray‘s full profile, request access.

Request a free trial

XSpray Executive Team (4)

Name Title Board Seat Contact Info
Per Andersson Ph.D Chief Executive Officer
Mustafa Demirbüker Ph.D Science Director & Co-Founder
Gérald Jesson Vice President, Operations
To view XSpray’s complete executive team members history, request access »

XSpray Board Members (9)

Name Representing Role Since
Carl-Johan Spak Ph.D Recipharm Board Member 000 0000
Hakan Nykvist XSpray Co-Founder & Board Member 000 0000
Hans Arwidsson Ph.D Self Board Member 000 0000
Jan Erik Nyström Self Board Member 000 0000
Maris Hartmanis Ph.D XSpray Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

XSpray Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

XSpray Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore XSpray‘s full profile, request access.

Request a free trial